Chemoprevention of breast cancer: Recommendations and rationale

Annals of Internal Medicine

Volumn 137, Issue 1, 2002, Pages 56-58

  Berg, Alfred O ^a   Allan, Janet D ^a   Frame, Paul ^a   Homer, Charles J ^a   Johnson, Mark S ^a   Klein, Jonathan D ^a   Lieu, Tracy A ^a   Mulrow, Cynthia D ^a   Orleans, Tracy C ^a   Peipert, Jeffrey F ^a   Pender, Nola J ^a   Siu, Albert L ^a   Teutsch, Steven M ^a   Westhoff, Carolyn ^a   Woolf, Steven H ^a  

^a AGENCY FOR HEALTHCARE RESEARCH AND QUALITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR; RALOXIFENE; TAMOXIFEN;

BREAST CANCER; CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG EFFICACY; ENDOMETRIUM CANCER; HOT FLUSH; HUMAN; OSTEOPOROSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK MANAGEMENT; SHORT SURVEY; STROKE; THROMBOEMBOLISM; UNITED STATES;

EID: 0037008085     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-137-1-200207020-00016     Document Type: Short Survey

References (4)

1. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer
2. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: Tamoxifen and raloxifene
3. Chemoprevention of breast cancer. A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer